Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2017
SIETES contiene 91804 citas

 
 
 1 a 20 de 196 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]
2. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
3. Cita con resumen
Anónimo. FDA approves generic versions of rosuvastatin calcium. DIA Daily 2016:1. [Ref.ID 100504]
4.Tiene citas relacionadas Cita con resumen
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Silwa K, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Accini JL, McKelvie R, Pogue J, Jung H, Liu L, Díaz R, Dans A, Dagenais G, for the HOPE-3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374:2032-43. [Ref.ID 100363]
5.Tiene citas relacionadas Cita con resumen
Yusuf S, Bosch J, Dagenais G, Xavier D, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJG, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sánchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Díaz R, Lonn E, for the HOPE-3 Investigators. Cholesterol lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31. [Ref.ID 100362]
6.Tiene citas relacionadas Cita con resumen
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Pals P, Díaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJG, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Hung H, Dagenais G, Yusuf S, for the HOPE-3 Investigators. Blood-pressure lowering in intermediate. Risk persons without cardiovascular disease. N Engl J Med 2016;374:2009-20. [Ref.ID 100361]
7. Cita con resumen
Ezquerra Pérez G, Martín de la Nava MA, Álvarez-Cienfuegos A, Montaño Barrientos A, Baquero Barroso MJ, Rubio Núñez PL, Gómez Santana MC, Gavilán Moral E, Candela Marroquín E, Sánchez Robles GA. Revisión GRADE de estatinas en población con = 90% en prevención primaria cardiovascular. Sección 3: Efectos adversos. II. Miopatías.. Grupo Evalmed-GRADE 2016:21 de enero. [Ref.ID 99983]
8. Cita con resumen
Anónimo. Lédipasvir + sofosbuvir. Prescrire 2015;35:732-8. [Ref.ID 99845]
9.Tiene citas relacionadas Cita con resumen
Mintzes B. When drugs don’t make it to market. BMJ 2015;350:h2852. [Ref.ID 99188]
10. Cita con resumen
11. Cita con resumen
Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, Shariff SZ, Gomes T, Mamdani M, Gandhi S, Dixon S, Garg AX. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015;187:174-80. [Ref.ID 98758]
12. Cita con resumen
Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, Rahme E, Tamim H, Lipscombe L, for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ 2014;348:g3244. [Ref.ID 98059]
13. Cita con resumen
Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014;60:679-86. [Ref.ID 97764]
14.Tiene citas relacionadas Cita con resumen
Spence D. Statins for all. BMJ 2014;348:g1899. [Ref.ID 97354]
15.Enlace a cita original
Tonelli M, Wanner Ch, for the Kidney disease: improving global outcomes lipid guideline development work group members. Lipid management in chronick Kidney disease: synopsis of the Kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182-93. [Ref.ID 97317]
16. Cita con resumen
Anónimo. Simeprevir (Olysio) for chronic hepatitis C. Med Lett Drugs Ther 2014;56:1-2. [Ref.ID 97179]
17.Tiene citas relacionadas Cita con resumen
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:14. [Ref.ID 95914]
18.Tiene citas relacionadas
Huupponen R, Viikari J. Statins and the risk of developing diabetes. BMJ 2013;346:7. [Ref.ID 95909]
19. Cita con resumen
Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized controlled trials. Circulation: Cardiovascular Quality and Outcomes 2013;6:390-9. [Ref.ID 95648]
20. Cita con resumen
Chung Y-H, Lee Y-C, Chang C-H, Lin M-S, Lin J-W, Lai MS. Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. Pharmacoepidemiol Drug Saf 2013;22:583-92. [Ref.ID 95562]
Seleccionar todas
 
 1 a 20 de 196 siguiente >>